Oral immunization of raccoons and skunks with a canine adenovirus recombinant rabies vaccine
Oral immunization of raccoons and skunks with a canine adenovirus recombinant rabies vaccine
复制标题
DOI：
10.1016/j.vaccine.2009.09.030
复制
发表时间：
2009-11-27
期刊：
影响因子：
5.5
通讯作者：
Rupprecht, Charles E.
中科院分区：
文献类型：
--
作者：
Henderson, Heather;Jackson, Felix;Rupprecht, Charles E.
口服疫苗接种是野生动物狂犬病控制计划的重要组成部分。目前，牛痘-狂犬病糖蛋白重组病毒是唯一在美国获得许可的口服狂犬病疫苗。而且它对臭鼬不起作用。在目前的研究中，圈养浣熊和臭鼬被用来评估一种通过将狂犬病病毒糖蛋白基因整合到犬腺病毒血清2型载体(CAV2-RVG)中而开发的疫苗。口服CAV2-RVG疫苗的7只浣熊中有7只产生了病毒中和抗体，并在致死攻击中存活下来。在接受10倍不同稀释度CAV2-RVG的两个实验组的6只臭鼬中，5只和6只产生了中和抗体，并在攻击中存活下来。这项初步研究的结果表明，CAV2-RVG能刺激浣熊和臭鼬对狂犬病的保护性免疫。爱思唯尔有限公司出版。
Oral vaccination is an important part of wildlife rabies control programs. Currently, the vaccinia-rabies glycoprotein recombinant virus is the only oral rabies vaccine licensed in the United States. and it is not effective in skunks. In the current study, captive raccoons and skunks were used to evaluate a vaccine developed by incorporating the rabies virus glycoprotein gene into a canine adenovirus serotype 2 vector (CAV2-RVG). Seven of 7 raccoons orally vaccinated with CAV2-RVG developed virus neutralizing antibodies and survived lethal challenge. Five of 5 and 6 of 6 skunks in 2 experimental groups receiving 10-fold different dilutions of CAV2-RVG developed neutralizing antibodies and survived challenge. The results of this preliminary study suggest that CAV2-RVG stimulates protective immunity against rabies in raccoons and skunks. Published by Elsevier Ltd.